Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stella PharmaTSE:4888 -0.73%75 PS Ratio is 43.26 as of Sep. 14, 2026, which is 26% below its 10-year median of 58.14. GuruFocus rates TSE:4888 with a GF Score™ of 75/100 and a GF Value™ of 円371.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 940 Biotechnology companies, Stella Pharma ranks worse than 76.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Stella Pharma's share price is 円408.00.
Stella Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円9.43. Hence, Stella Pharma's PS Ratio for today is 43.26.
The historical rank and industry rank for Stella Pharma's PS Ratio or its related term are showing as below:
TSE:4888'
s PS Ratio Range Over the Past 10 Years
Min: 26.39 Med: 58.14 Max: 396.59
Current: 43.26
During the past 8 years, Stella Pharma's highest PS Ratio was 396.59. The lowest was 26.39. And the median was 58.14.
TSE:4888's PS Ratio is ranked worse than 76.38% of 940
companies
in the Biotechnology industry
Industry Median: 9.33
vs TSE:4888: 43.26
Stella Pharma Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Stella Pharma was -67.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.60% per year.
During the past 8 years, Stella Pharma's highest 3-Year average Revenue per Share Growth Rate was 100.70% per year. The lowest was -5.40% per year. And the median was 6.20% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Stella Pharma PS Ratio Related Terms
Stella Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Stella Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stella Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Stella Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Stella Pharma's Share Price of today is 円408.00. Stella Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Stella Pharma (TSE:4888) has a PS Ratio of 43.26 as of Sep. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Stella Pharma and its competitors. This is 26% below median its historical median of 58.14. Over the past decade, Stella Pharma's PS Ratio has ranged from 26.39 to 396.59. According to the industry distribution chart, Stella Pharma ranks #718 out of 940 companies in the Biotechnology industry, placing it in the top 76.4%.
Is Stella Pharma's PS Ratio too high?
Stella Pharma's current PS Ratio of 43.26 is 26% below median its 10-year median of 58.14. Over the past 10 years, this metric has ranged from a low of 26.39 to a high of 396.59. The Biotechnology industry median PS Ratio is 9.33. Stella Pharma's value of 43.26 is 363.7% above this industry median. Based on the distribution chart, Stella Pharma ranks #718 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stella Pharma has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #718 out of 940 companies for PS Ratio. This places Stella Pharma in the lower half of its industry. The industry median PS Ratio is 9.33. Stella Pharma's value of 43.26 is 363.7% above this benchmark. Historically, Stella Pharma's own PS Ratio has ranged from 26.39 to 396.59 over the past decade. While the company's 10-year median is 58.14 vs. the industry median of 9.33, Stella Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.33, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stella Pharma's current PS Ratio of 43.26 is 363.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Stella Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stella Pharma's current PS Ratio is 43.26, which is 26% below median its own 10-year median of 58.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円371.49, compared to a current price of 円408.00 — trading 9.8% above its estimated fair value. The current PS Ratio is 43.26, which is 26% below median its 10-year median of 58.14 and 363.7% above the Biotechnology industry median of 9.33. Stella Pharma's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current PS Ratio is 43.26 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be overvalued.
The current stock price of 円408.00 is trading 9.8% above its estimated GF Value™ of 円371.49.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
PS Ratio: 43.26 (26% below median its 10-year median of 58.14)
GF Value™: 円371.49 vs. price of 円408.00 (9.8% above fair value)
Industry Position: 363.7% above the Biotechnology median (#718 of 940)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
75GF Score
Get the complete analysis for TSE:4888
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
